Journal
NUTRIENTS
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/nu10121950
Keywords
BRAF melanoma; chemotherapeutics; extra virgin oil; Oleuropein; olive leaf extract
Categories
Funding
- Istituto Toscano Tumori and Ente Cassa di Risparmio di Firenze
Ask authors/readers for more resources
Oleuropein (Ole), a secoiridoid glucoside present in Olea europaea leaves, gained scientific interest thanks to its several biological properties, including the anticancer one. We verified whether Ole might potentiate the cytotoxicity of conventional drugs used to treat melanoma, disclosing a potentially new therapeutic strategy. We tested the cytotoxic action of Ole alone or in combination with chemotherapeutics on A375 human melanoma cells. We found that Ole was able, at a dose of 500 mu M, to stimulate apoptosis, while at a non-toxic dose of 250 mu M, it affected cell proliferation and induced the downregulation of the pAKT/pS6 pathway. A dose of 250 mu M Ole did not potentiate the effect of Vemurafenib (PLX4032), but it succeeded in increasing the cytotoxic effect of Dacarbazine (DTIC). The major effect was found in the association between Ole and Everolimus (RAD001), also on PLX4032-resistant BRAF melanoma cells, which possibly cooperate in the inhibition of the pAKT/pS6 pathway. Of interest, an olive leaf extract enriched in equimolar Ole was more effective and able to further improve DTIC and RAD001 efficacy on BRAF melanoma cells with respect to Ole alone. Therefore, Ole represents a natural product able to potentiate a wide array of chemotherapeutics against BRAF melanoma cells affecting the pAKT/pS6 pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available